Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/8/2024 | $15.00 → $20.00 | Neutral → Buy | ROTH MKM |
10/20/2023 | $12.00 | Neutral | ROTH MKM |
9/12/2023 | Buy → Neutral | BTIG Research | |
9/12/2023 | Buy → Hold | Stifel | |
7/19/2023 | $27.00 | Buy | BTIG Research |
3/4/2022 | $41.00 → $45.00 | Hold → Buy | Stifel |
ROTH MKM upgraded Orthofix from Neutral to Buy and set a new price target of $20.00 from $15.00 previously
ROTH MKM initiated coverage of Orthofix with a rating of Neutral and set a new price target of $12.00
BTIG Research downgraded Orthofix from Buy to Neutral
Monday, November 18, 2024 at 8:35 am Eastern Time Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the Stifel 2024 Healthcare Conference in New York. Management is scheduled to present on Monday, November 18, 2024 at 8:35 am ET. Interested parties can access the live and archived webcast of the presentation in the "Events & Presentations" section of the Orthofix investor relations website at ir.orthofix.com. Internet Posting of Information Orthofix routinely posts information that may be important to investors in the "Investors" section of its website at www.orthofix.com. The Company encourages investo
Company to Host Conference Call on Thursday, November 7, 2024 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2024 financial results on Thursday, November 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations,
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the presentation of new data supporting the use of Orthofix's proprietary Pulsed Electromagnetic Field (PEMF) stimulation to increase fusion rates as an adjunct to lumbar spine fusion surgery. Patients treated with the SpinalStim™ bone growth therapy device demonstrated a high rate of successful fusion with significant improvements in pain, function and quality of life, despite having risk factors for pseudarthrosis. The abstract will be presented by Dr. Marc Weinstein, an orthopedic spine surgeon at the Florida Orthopaedic Institute in Tampa, Florida, at the North American Spine Society (NASS
4 - Orthofix Medical Inc. (0000884624) (Issuer)
3 - Orthofix Medical Inc. (0000884624) (Issuer)
3 - Orthofix Medical Inc. (0000884624) (Issuer)
SC 13D/A - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G - Orthofix Medical Inc. (0000884624) (Subject)
SC 13G/A - Orthofix Medical Inc. (0000884624) (Subject)
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Patrick Fisher as President of the Orthofix Global Orthopedics business. In this role, Fisher will serve on the company's Executive Leadership team, reporting to Orthofix President and CEO Massimo Calafiore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815706187/en/Patrick Fisher, President of Orthofix Global Orthopedics (Photo: Business Wire) Fisher joins Orthofix from Stryker Corporation, a global medical technology company where he served as the Vice President and General Manager of the Foot and Ankle b
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Stephanie Walsh as Chief Human Resources Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716004057/en/Stephanie Walsh, Chief Human Resources Officer, Orthofix (Photo: Business Wire) A seasoned human resources executive, Walsh joins Orthofix from ResMed Inc., a San Diego-based medical device company, where she served most recently as Vice President of Transformation. During her tenure at ResMed, she also held multiple HR leadership positions including Vice President, People - SaaS, where she led the H
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Michael Finegan as Chair of the Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624766470/en/Michael Finegan, Chair of the Orthofix Board of Directors. (Photo: Business Wire) Finegan was appointed to the Orthofix Board in December 2023. He is CEO at Acera Surgical, a bioscience company developing and commercializing a portfolio of fully engineered synthetic materials for soft tissue repair and regenerative medicine. Prior to joining Acera, Finegan spent 14 years at Orthofix where he served
S-8 - Orthofix Medical Inc. (0000884624) (Filer)
S-8 - Orthofix Medical Inc. (0000884624) (Filer)
10-Q - Orthofix Medical Inc. (0000884624) (Filer)
The Rodeo Telescopic Nail is a device indicated to surgically treat deformities or fractures in patients suffering from osteogenesis imperfecta (OI). The nail implant serves to stabilize the patient's limb while also elongating (or telescoping) to accommodate the natural growth of pediatric patients.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut the price target for ZoomInfo Technologies Inc. (NASDAQ:ZI) from $24 to $15. Piper Sandler analyst Brent Bracelin downgraded the stock from Overweight to Neutral. ZoomInfo Technologies shares fell 3.6% to close at $16.02 on Tuesday. See how other analysts view this stock. Baird boosted the price target for Datadog, Inc. (NASDAQ:DDOG) from $130 to $140. Baird analyst William Power upgraded the stock from Neutral to Outperform. Datadog shares fell 11.5% to close at $112.40 on Tuesda
Roth MKM analyst Jason Wittes upgrades Orthofix Medical (NASDAQ:OFIX) from Neutral to Buy and raises the price target from $15 to $20.
Company to Host Conference Call on Thursday, November 7, 2024 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2024 financial results on Thursday, November 7, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations,
Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2024 and increased its full-year 2024 financial guidance. Recent Highlights Second quarter 2024 net sales of $198.6 million, an increase of 6% on a reported and constant currency basis compared to second quarter 2023 Bone Growth Therapies (BGT) net sales growth of 12% compared to second quarter 2023, marking six consecutive quarters with double-digit net sales increases U.S. Spine Fixation1 net sales growth of 12% compared to second quarter 2023, driven by distribution expansion and further penetration in existing accounts Global Orthopedics net sales growth of 5% on
Company to Host Conference Call on Tuesday, August 6, 2024 at 8:30 am ET Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that it will release its second quarter 2024 financial results on Tuesday, August 6, 2024 before market open. The Company will host a conference call and webcast to review results at 8:30 am ET the same day. Interested parties may access the conference call by dialing (888) 330-2508 in the U.S., and (240) 789-2735 in all other locations, and referencing the event passcode 9556380. A replay of the call will be available for three weeks by dialing (800) 770-2030 in the U.S., and (647) 362-9199 in all other locations,